[1] |
张建波, 宋魏, 王媛媛, 等. 肺转移性肿瘤113例临床病理学观察[J]. 心肺血管病杂志, 2017, 36(12): 979-982, 987.
|
|
ZHANG J, SONG W, WANG Y, et al. Clicical and pathological analysis of 113 cases of lung metastatic tumors[J]. J Cardiovasc Pulm Dis, 2017, 36(12): 979-982, 987.
|
[2] |
ROHREN E M, TURKINGTON T G, COLEMAN R E. Clinical applications of PET in oncology[J]. Radiology, 2004, 231(2): 305-332.
doi: 10.1148/radiol.2312021185
pmid: 15044750
|
[3] |
IAGARU A, CHAWLA S, MENENDEZ L, et al. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas[J]. Nucl Med Commun, 2006, 27(10): 795-802.
doi: 10.1097/01.mnm.0000237986.31597.86
pmid: 16969262
|
[4] |
魏昊, 兰晓莉, 廖姗珊, 等. 18F-FDG PET/CT显像评价胃癌肺转移[J]. 华中科技大学学报(医学版), 2016, 45(2): 141-144.
|
|
WEI H, LAN X, LIAO S, et al. Evaluation of lung metastasis in gastric cancer with 18F-FDG PET/CT imaging[J]. Acta Med Univ Sci Technol Huazhong, 2016, 45(02): 141-144.
|
[5] |
HATHI D K, JONES E F. 68Ga FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. Radiol Imaging Cancer, 2019, 1(1): e194003.
doi: 10.1148/rycan.2019194003
|
[6] |
LINDNER T, LOKTEV A, ALTMANN A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl Med, 2018, 59(9): 1415-1422.
|
[7] |
CHEN H, ZHAO L, RUAN D, et al. Usefulness of[68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F] FDG PET/CT findings[J]. Eur J Nucl Med Mol Imaging, 2021, 48(1): 73-86.
doi: 10.1007/s00259-020-04940-6
|
[8] |
KOERBER S A, STAUDINGER F, KRATOCHWIL C, et al. The role of 68Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl Med, 2020, 61(9): 1331-1336.
doi: 10.2967/jnumed.119.237016
|
[9] |
CHEN H J, PANG Y Z, WU J X, et al. Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1820-1832.
doi: 10.1007/s00259-020-04769-z
|
[10] |
PANG Y Z, ZHAO L, LUO Z M, et al. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers[J]. Radiology, 2021, 298(2): 393-402.
doi: 10.1148/radiol.2020203275
|
[11] |
DING F, HUANG C, LIANG C, et al. 68Ga-FAPI-04 vs 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer[J]. Eur J Nucl Med Mol Imaging, 2021, 49(1): 290-300.
doi: 10.1007/s00259-021-05442-9
|
[12] |
GIESEL F L, KRATOCHWIL C, LINDNER T, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers[J]. J Nucl Med, 2019, 60(3): 386-392.
doi: 10.2967/jnumed.118.215913
|
[13] |
谢昭娟, 全志永, 赵小虎, 等. 胰腺癌摄取 68Ga-FAPI-04的PDX动物模型及临床PET/CT显像研究[J]. 中华核医学与分子影像杂志, 2021, 41(12): 722-726.
|
|
XIE Z, QUAN Y, ZHAO X, et al. Uptake of 68Ga-FAPI-04 in pancreatic cancer-PDX animal model and its clinical PET/CT imaging[J]. Chin J Nucl Med Mol Imaging, 2021, 41(12): 722-726.
|
[14] |
CHEN R H, ZHOU X, LIU J J, et al. Relationship between 18F-FDG PET/CT findings and HER2 expression in gastric cancer[J]. J Nucl Med, 2016, 57(7): 1040-1044.
doi: 10.2967/jnumed.115.171165
|
[15] |
YANG Z, LIU S, SUN Y, et al. 18F-FDG PET/CT metabolic parameters and HER2 expression in colorectal cancer[J]. Neoplasma, 2021, 68(4): 875-881.
doi: 10.4149/neo_2021_200803N807
|